Why Patients Develop HFpEF
HFpEF develops through a systemic inflammatory and metabolic cascade triggered by cardiometabolic comorbidities—particularly hypertension, obesity, diabetes, and aging—that converge to produce myocardial remodeling, diastolic dysfunction, and elevated left ventricular filling pressures. 1, 2
Primary Pathophysiologic Drivers
Cardiometabolic Foundation
The dominant mechanism begins with cardiometabolic risk factors that create a pro-inflammatory state 3, 2:
- Hypertension remains the most common and strongest contributing factor, causing chronic afterload stress and ventricular remodeling 4
- Obesity and diabetes drive systemic inflammation, impaired nitric oxide signaling, and metabolic dysfunction 2
- Advanced age independently contributes through cellular senescence and cumulative oxidative stress 5
Cellular and Molecular Mechanisms
These systemic factors trigger specific pathologic changes 2:
- Inflammation and fibrosis: Chronic inflammatory activation leads to myocardial and interstitial fibrosis
- Impaired nitric oxide signaling: Endothelial dysfunction reduces NO bioavailability, promoting myocardial stiffness
- Sarcomere dysfunction: Direct impairment of cardiomyocyte relaxation
- Mitochondrial and metabolic defects: Energy substrate utilization becomes inefficient
- Coronary microvascular dysfunction: Emerging evidence suggests myocardial ischemia from microvascular disease may be a mechanistic driver, particularly in older women with multiple comorbidities 6
Hemodynamic Consequences
The cellular changes manifest as specific hemodynamic abnormalities 2:
- Left ventricular structural changes: Concentric remodeling with increased wall thickness
- Diastolic dysfunction: Impaired ventricular relaxation and increased chamber stiffness
- Left atrial myopathy: Progressive atrial enlargement and dysfunction
- Pulmonary hypertension: Backward transmission of elevated filling pressures
- Right ventricular dysfunction: Secondary to pulmonary vascular disease
- Chronotropic incompetence: Inability to augment heart rate appropriately with exercise
- Systemic vascular dysfunction: Arterial stiffening and impaired vasodilation
Multi-Organ System Involvement
HFpEF is fundamentally a systemic syndrome, not just a cardiac disease 2:
- Skeletal muscle: Deconditioning and metabolic abnormalities
- Peripheral vasculature: Endothelial dysfunction and reduced vasodilatory reserve
- Lungs: Pulmonary vascular remodeling
- Kidneys: Cardiorenal syndrome with bidirectional injury 7, 8
- Brain: Cognitive impairment from chronic hypoperfusion
Clinical Phenotypes and Heterogeneity
The syndrome represents a family of endotypes unified by diastolic dysfunction but driven by distinct mechanisms 3:
- Cardiometabolic phenotype: Obesity, diabetes, metabolic syndrome predominant
- Hypertensive phenotype: Long-standing hypertension with concentric remodeling
- Atrial fibrillation phenotype: AF as both cause and consequence, complicating diagnosis and management 9
- Cardiorenal phenotype: CKD with overlapping inflammatory and hemodynamic pathways 7, 8
Key Clinical Pitfalls
Critical point: Traditional teaching that HFpEF results exclusively from diastolic dysfunction is outdated 5. The pathophysiology extends to:
- Limitations in systolic reserve (despite preserved resting EF)
- Pulmonary and systemic vascular dysfunction
- Autonomic dysregulation
- Peripheral organ impairments
Important caveat: While hypertension historically was considered the primary driver, HFpEF continues to progress despite adequate blood pressure control, indicating that additional mechanisms beyond afterload are operative 6.
The Rising Epidemic
The incidence of HFpEF continues to rise even as overall heart failure rates stabilize, now accounting for >50% of all heart failure cases 1. This reflects:
- Aging population demographics
- Increasing prevalence of obesity and diabetes
- Improved survival from other cardiovascular diseases
- Better recognition and diagnosis